Learning from drug disasters and reforming medicines regulation

Critical Public Health

Volumn 13, Issue 3, 2003, Pages 269-279

  Abraham, John ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENOXAPROFEN; BENZODIAZEPINE DERIVATIVE; HYPNOTIC AGENT; PLACEBO; THALIDOMIDE; TRIAZOLAM;

AMNESIA; ANXIETY DISORDER; ARTICLE; CARCINOGEN TESTING; CLINICAL PROTOCOL; CLINICAL STUDY; DEPRESSION; DISASTER; DRUG APPROVAL; DRUG CARCINOGENICITY; DRUG CONTROL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HALLUCINATION; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; INSOMNIA; LABORATORY TEST; LEARNING; LICENSING; MENTAL DISEASE; NEPHROBLASTOMA; NONHUMAN; PARANOIA; PRESCRIPTION; PUBLIC HEALTH SERVICE; TOXICITY TESTING; WORLD HEALTH ORGANIZATION;

EID: 85047688408     PISSN: 09581596     EISSN: None     Source Type: Journal    
DOI: 10.1080/0958159032000114462     Document Type: Article

References (19)

1. Abraham, J. (1995) Science, Politics and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation (London/New York, UCL/St Martins Press).
2. Abraham, J. & Lewis, G. (1998) Secrecy and transparency of medicines licensing in the EU. Lancet, 352, pp. 480-482.
3. Abraham, J. & Lewis, G. (2000) Regulating Medicines in Europe: Competition, Expertise and Public Health (London, Routledge).
4. Abraham, J. & Reed, T. (2001) Trading risks for markets: the international harmonisation of pharmaceuticals regulation. Health, Risk & Society, 3, pp. 113-128.
5. Abraham, J. & Sheppard, J. (1997) Democracy, technocracy and the secret state of medicines control: expert and non-expert perspectives. Science, Technology & Human Values, 22, pp. 139-167.
6. Anon. (1962) Drug toxicity: debate on drug control. Pharmaceutical Journal, 189, pp. 523-524.
7. Anon. (1996) FDA says Halcion a matter for Justice Department. Scrip, 2135, p. 17.
8. Association of the British Pharmaceutical Industry. Guidelines for Preclinical and Clinical Testing of New Medicinal Products, Part 1: Laboratory Investigations (Geneva, WHO), p. 25.
9. Braithwaite, J. (1984) Corporate Crime in the Pharmaceutical Industry (London, Routledge & Kegan Paul).
10. Dukes, M. N. G. & Swartz, B. (1988) Responsibility for Drug-induced Injury (Amsterdam, Elsevier), p. 3.
11. Dyer, C. (1992) Drug tester barred after Halcion trials. Guardian 13 February.
12. Food and Drug Administration (1992) Halcion update. FDA Talk Paper, 14 February.
13. Hottendorf, G. H. & Ingraham, K. J. (1968) Spontaneous nephroblastomas in laboratory rats. Journal of the American Veterinary and Medical Association, 153, p. 828.
14. Lazarou, J., Pomeranz, B. H. & Corey, P. N. (1998) Incidence of adverse drug reactions in hospitalised patients. Journal of the American Medical Association, 279, pp. 1200-1205.
15. Pharmaceutical Manufacturers Association (1977) Guidelines for the Assessment of Drug and Medical Device Safety in Animals (Pharmaceutical Manufacturers Association), p. 58.
16. Rawlins, M. D. (1988) Spontaneous reporting of adverse reactions, I: The data. British. Journal of Clinical Pharmacology, 26, pp. 1-5.
17. Vaughan, D. (1983) Controlling Unlawful Behaviour: Social Structure and Corporate Misconduct (Chicago and London, University of Chicago Press), pp. 106-108.
18. Veldkamp, W., Rudzik, A. D. & Metzler, C. M. (1973) Upjohn Pharmaceutical Research and Development Technical Report, U-33,030: Six-Week Tolerance Study, SPSM Protocol No. 321, Phase II Study, 27 August.
19. World Health Organisation (1969) Principles for the testing and evaluation of drugs for carcinogenicity. Technical Report Series, 426, p. 15.